MIND MEDICINE MINDMED INC. [MMEDF: OTCQB]

3.32 -0.12 (-3.49%) 3:53 PM Delayed 15 minutes

Open	$3.54	Daily Range	$3.15-$3.54
Prev. Close	$3.44	52 Week Range	$0.0833-$5.07
Volume	2,413,201

Quote Data Realtime

Inside Quote
Bid	Ask	Last Inside Change
$3.31 x 525 shares	$3.32 x 9212 shares	02/26 4:00 PM EST

Level II Quote Montage

BID

ASK

MMID	Bid Price	Bid Size	Date/Time
CDEL	3.31	525	15:59
GTSM	3.30	2616	15:59
NITE	3.30	1550	15:59
ETRF	3.30	847	15:59
INTL	3.30	300	15:59
VALX	3.29	5800	15:59
JANE	3.29	5000	15:59
OTCX	3.29	9200	15:59
CSTI	3.28	100	15:59
VNDM	2.99	6000	09:30
PAUL	2.88	100	02/23
MAXM	2.71	8900	09:30
LAFC	2.52	100	12/22
VERT	1.97	100	01/28
PUMA	1.42	100	08:10
BGCE	1.00	100	02/23
WABR	1.00	100	02/01
MCAP	0.80	1000	15:59
cCANT	2.52	100	02/23

MMID	Ask Price	Ask Size	Date/Time
NITE	3.32	8253	15:59
CSTI	3.32	959	15:59
OTCX	3.34	1500	15:59
INTL	3.34	800	15:59
ETRF	3.35	100	15:59
VALX	3.36	2900	15:59
JANE	3.38	5000	15:59
CDEL	3.38	1000	15:59
GTSM	3.40	800	15:21
MAXM	3.50	100	09:30
VNDM	3.50	100	11:48
PAUL	4.50	100	02/17
VERT	5.00	100	01/22
PUMA	5.44	100	08:10
LAFC	5.45	100	12/14
MCAP	5.86	100	15:59
BGCE	5.98	100	02/23
WABR	100.00	100	02/12
cCANT	6.00	100	01/21

The quotes displayed here are published by market makers on the OTC Markets Group Inc. electronic inter-dealer quotation and trading system for OTC securities. Please see Terms of Service and Risk Warning for more information.

MMID - Market maker quotation published in OTC Link that meets the Inside market | MMID - Market maker quotation published in OTC Link | cMMID - Closed quote | Unpriced - Unpriced quote in OTC Link | MMIDu - Unsolicited market maker quotation published in OTC Link

forbes

This New York City Pharma Startup Wants To Turn LSD Into An FDA-Approved Medicine For Anxiety Disorder

Mind Medicine Inc., a New York-based psychedelic drug development company, that counts Shark Tank star Kevin O’Leary and Toms Shoes founder Blake Mycoskie as investors, has acquired the exclusive rights to eight clinical trials that are exploring the medicinal properties of the powerful hallucinogen lysergic acid diethylamide (LSD). One of the studies is an ongoing, placebo-controlled Phase 2 trial of LSD for the treatment of anxiety disorder.

read the full forbes article

https://www.forbes.com/sites/willyakowicz/2020/04/01/this-new-york-city-pharma-startup-wants-to-turn-lsd-into-an-fda-approved-medicine-for-anxiety-disorder/#754c87713293

This New York City Pharma Startup Wants To Turn LSD Into An FDA-Approved Medicine For Anxiety Disorder

Browse more articles